别孕甾酮
神经活性类固醇
抗抑郁药
焦虑
情绪障碍
抗焦虑药
神经营养因子
心理学
药理学
变构调节剂
神经科学
抑郁症动物模型
经前期烦躁障碍
γ-氨基丁酸受体
医学
内科学
精神科
受体
变构调节
激素
月经周期
作者
Shiyi Chen,Lijuan Gao,Xiaoyü Li,Yiping Ye
标识
DOI:10.1016/j.phrs.2021.105682
摘要
The neuroactive steroid allopregnanolone (ALLO) is an endogenous positive allosteric modulator of GABA type A receptor (GABAAR), and the down-regulation of its biosynthesis have been attributed to the development of mood disorders, such as depression, anxiety and post-traumatic stress disorder (PTSD). ALLO mediated depression/anxiety involves GABAergic mechanisms and appears to be related to brain-derived neurotrophic factor (BDNF), dopamine receptor, glutamate neurotransmission, and Ca2+ channel. In the clinical, brexanolone, as a newly developed intravenous ALLO preparation, has been approved for the treatment of postpartum depression (PPD). In addition, traditional antidepressants such as selective serotonin reuptake inhibitor (SSRI) could reverse ALLO decline. Recently, the translocation protein (TSPO, 18 kDa), which involves in the speed-limiting step of ALLO synthesis, and ALLO derivatization have been identified as new directions for antidepressant therapy. This review provides an overview of ALLO researches in animal model and patients, discusses its role in the development and treatment of depression/anxiety, and directs its therapeutic potential in future.
科研通智能强力驱动
Strongly Powered by AbleSci AI